Evidence map›Paper›PMID 40531969›Full record

ArticleScience translational medicine2025

Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion.

Kristen A Rodrigues, Yiming J Zhang, Jonathan Lam, Aereas Aung, Duncan M Morgan, Anna Romanov, Laura Maiorino, Parisa Yousefpour, Grace Gibson, Gabriel Ozorowski and 8 more

Abstract read
In one paragraph

Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Highlights of 2025: advances in germinal centers.Immunology and cell biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Atomic Layering Thermostable Antigen and Adjuvant (ALTAbioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Kristen A RodriguesKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-0680-9834
Yiming J ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-8102-3815
Jonathan LamKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-2811-7177
Aereas AungKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Duncan M MorganKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-3253-1362
Anna RomanovKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-1239-4946
Laura MaiorinoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-8217-1337
Parisa YousefpourKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-0431-8131
Grace GibsonDepartment of Integrative, Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0002-8312-2953
Gabriel OzorowskiDepartment of Integrative, Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-9695-8138
Justin R GregoryKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-4526-3229
Parastoo AmlashiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-4801-1871
Richard VanKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Maureen BuckleyKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-9928-6402
Andrew B WardConsortium for HIV/AIDS Vaccine Development, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7153-3769
William R SchiefRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.ORCID 0000-0002-1120-0150
J Christopher LoveKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-0921-3144
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-8637-1405

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Virology and ImmunologyP01AI048240 · NIAID · UNIVERSITY OF WASHINGTON · PI RUPRECHT, RUTH MARGRIT · 2000 to 2020
$46.7M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR37AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Shane P Crotty, Darrell J Irvine · 2021 to 2026
$5.4M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR61AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2021 to 2023
$4.7M
Maximizing germinal centers and somatic hypermutation to HIV Env immunogensR01AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2016 to 2020
$4.3M
Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR33AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2024 to 2025
$3.2M
Immune engineering of optimized sequential immunization strategies for HIV vaccinesR33AI161297 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2024 to 2025
$2.5M
Immune engineering of optimized sequential immunization strategies for HIV vaccinesR61AI161297 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2021 to 2023
$2.3M
Controlling Vaccine Kinetics with Small Molecule DrugsF32AI164829 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI YOUSEFPOUR, PARISA · 2022 to 2024
$184k
Howard Hughes Medical InstituteNCI NIH HHS P30 CA014051NIAID NIH HHS F32 AI164829NIAID NIH HHS P01 AI048240NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI125068NIAID NIH HHS R33 AI161297NIAID NIH HHS R33 AI161818NIAID NIH HHS R37 AI125068NIAID NIH HHS R61 AI161297NIAID NIH HHS R61 AI161818NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Vaccine adjuvants play important roles in shaping the humoral response to immunization. Here, we analyzed mechanisms of action of a clinically relevant combination adjuvant strategy, where phosphoserine (pSer)-tagged immunogens bound to aluminum hydroxide (alum) adjuvant, promoting prolonged antigen release to draining lymph nodes, are combined with a saponin nanoparticle adjuvant termed SMNP, which alters lymph flow and antigen entry into lymph nodes. When used with a stabilized HIV envelope trimer antigen in mice, this combined adjuvant approach promoted substantial enhancements in germinal center and antibody responses relative to either adjuvant alone. Using single-cell RNA and B cell receptor sequencing, we found that the alum-pSer/SMNP combination augmented the clonal expansion and diversity of the germinal center B cell repertoire, coincident with an increased proportion of S-phase germinal center B cells and expression of positive selection markers. Moreover, we found that the combination adjuvant approach, but not alum-pSer delivery or SMNP alone, promoted accumulation of intact antigen on follicular dendritic cells, reflecting integrated effects of slow antigen delivery and altered lymph node uptake. Genetic ablation of

Indexed as

AntigensB-LymphocytesGerminal CenterVaccinesAdjuvants, ImmunologicAnimalsDendritic Cells, FollicularFemaleLymph NodesMiceMice, Inbred C57BLSaponinsAdjuvants, ImmunologicAntigensSaponinsVaccines

Identifiers

PMID40531969
PMCPMC12335825

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.